Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Harnessing the power of real-world data requires careful consideration

By Brian Buntz | November 9, 2021

Grid

Image courtesy of Pixabay

The use of real-world data (RWD) has boomed during the pandemic, but the pharmaceutical industry has only scratched the surface in terms of tapping its potential.

The use of such data, however, is set to grow, given the FDA’s recent release of new guidance concerning the use of electronic health records and medical claims data for regulatory decision-making for drugs and biologics.

Two years ago, some people in the industry questioned “whether RWD would have any application in the world of clinical development,” said Jeff Elton, CEO of ConcertAI. Those days are over. It is now clear that RWD is important, given the FDA guidance and the surge in use in RWD during the pandemic.

The level of rigor concerning real-world data is set to grow, given FDA’s feedback concerning the use of such data in clinical trial designs, trial interpretation. “The expectations for RWD are going to be higher, and methodologies are going to improve substantially,” Elton predicted.

However, making the most of real-world data requires a rethinking of research as an activity that occurs in labs or clinics. With RWD, it is possible to think of research as a continuum that precedes the official start date of a clinical trial while continuing after it ends.

Doing so requires identifying the available data sources, including electronic medical records (EMRs), medical claims data, radiological imaging, and independent laboratory data. Sometimes, the process requires integrating a variety of data sources, including data from multiple EMRs.

“You can have multiple clinical data types that may require different analyses,” Elton said.

While EMRs can contain uniquely valuable data, they can have both structured and unstructured data. The former involves machine-readable fields while the latter might consist of notes from nurses and physicians, including radiologists interpreting, say, the size of a tumor nodule.

A business rules engine (BRE) can help sift through the noise by using predefined logic. “But the business rules can also change the value of variables, depending on how you wrote the rules,” Elton said.

Therefore, it is vital to consider those business rules in study design to ensure data accuracy and transparency. “You make sure the rules have clinical meaning so that if a clinician read your rules, they’d say, ‘Yes, that’s how we look at the medical record,'” Elton said.

In oncology, for instance, such unstructured data can contain information related to adverse events, intermediate measures of response or cancer progression.

The recent FDA guidance provides feedback on creating designs of studies and approaches to ensure a high degree of rigor and ethics when working with RWD.

“The most important thing at the end of the day is, often, to let the question determine the data,” Elton said. “Don’t just say, ‘Here’s the data. I hope it does okay against this question of interest.'”


Filed Under: clinical trials, Drug Discovery
Tagged With: ConcertAI, FDA, real-world data, RWD
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Zoliflodacin wins FDA nod for treatment of gonorrhea
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE